Prevalence of Delayed Clinician Response to Elevated Prostate-Specific Antigen Values

Nepple, Kenneth G.; Joudi, Fadi N.; Hillis, Stephen L.; Wahls, Terry L.
April 2008
Mayo Clinic Proceedings;Apr2008, Vol. 83 Issue 4, p439
Academic Journal
OBJECTIVE: To assess the frequency of delayed response to an abnormal prostate-specific antigen (PSA) value. PATIENTS AND METHODS: Retrospective review of prostate cancer cases diagnosed between January 1, 2000, and December 31, 2005, in a rural Department of Veterans Affairs health care system serving 44,000 veterans across 2 states. Clinician response was defined as a reference to the elevated PSA result in clinical notes, orders for further evaluation, treatment of presumed prostatitis, or a urology visit or referral. Delay was measured as days between an abnormal PSA result and clinician response. RESULTS: We Identified 327 men who met inclusion criteria with an abnormal PSA value before prostate cancer diagnosis. At first PSA elevation, median age was 64 years; 94% were younger than 75 years. Of the 327 men, 253 (77.4%) had a timely (≤30 days) response to an abnormal PSA value; 23 (7.0%) had between 31 and 180 days; 24 (7.3%), between 181 and 360 days; and 27 (8.3%), more than 360 days between an abnormal PSA measurement and clinician response. The delayed group had nearly an additional year's (309 days) lapse before completed urologic consultation and prostate gland biopsy (313 days) as compared with the timely group. The presence of urologic symptoms, abnormal results from rectal examination, higher PSA values, and higher PSA velocity (P<.05) were associated with timely clinician response to an abnormal PSA measurement. CONCLUSION: in a cohort of men with prostate cancer and an antecedent abnormal PSA value, 15.6% had more than 180 days between an abnormal PSA measurement and clinician response. These findings add to the growing literature demonstrating that missed results occur more frequently than is generally appreciated. Improved systems for clinical data management are needed.


Related Articles

  • High placenta-specific 1/low prostate-specific antigen expression pattern in high-grade prostate adenocarcinoma. Ghods, Roya; Ghahremani, Mohammad-Hossein; Madjd, Zahra; Asgari, Mojgan; Abolhasani, Maryam; Tavasoli, Sanaz; Mahmoudi, Ahmad-Reza; Darzi, Maryam; Pasalar, Parvin; Jeddi-Tehrani, Mahmood; Zarnani, Amir-Hassan // Cancer Immunology, Immunotherapy;Dec2014, Vol. 63 Issue 12, p1319 

    Background: The scarcity of effective therapeutic approaches for prostate cancer (PCa) has encouraged steadily growing interest for the identification of novel antigenic targets. Placenta-specific 1 (PLAC1) is a novel cancer-testis antigen with reported ectopic expression in a variety of tumors...

  • Treatment of localized prostate cancer. Burchardt, Martin; Huland, Hartwig // World Journal of Urology;Feb2007, Vol. 25 Issue 1, p1 

    The authors reflect on the treatment of localized prostate cancer. They express that with prevalent use of prostate-specific antigen (PSA) for detection of prostate cancer, better chance of cure has been given and possibility of overtreatment has evolved. They point out that PSA has lacked of...

  • A rapid PSA half-life following docetaxel chemotherapy is associated with improved survival in hormone refractory prostate cancer. Hanninen, Mikael; Venner, Peter; North, Scott // Canadian Urological Association Journal;Oct2009, Vol. 3 Issue 5, p369 

    Introduction: Docetaxel chemotherapy prolongs survival in metastatic hormone-refractory prostate cancer (mHRPC), but many patients fail to respond to this therapy and there is potential for serious toxicity. Patients differ in their percent prostate-specific antigen (PSA) decline and rate of PSA...

  • Assessing Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial. Thompson, Ian M.; Ankerst, Donna Pauler; Chen Chi; Goodman, Phyllis J.; Tangen, Catherine M.; Lucia, M. Scott; Ziding Feng; Parnes, Howard L.; Coltman Jr., Charles A. // JNCI: Journal of the National Cancer Institute;4/19/2006, Vol. 98 Issue 8, p529 

    Background: Prostate-specific antigen (PSA) testing is the primary method used to diagnose prostate cancer in the United States. Methods to integrate other risk factors associated with prostate cancer into individualized risk prediction are needed. We used prostate biopsy data from men who...

  • Enzyme inhibitor effective against refractory PCa. Kuznar, Wayne // Urology Times;10/1/2009, Vol. 37 Issue 11, p24 

    The article discusses a study performed by researchers from Royal Mardsen Hospital in London, England which found that a specific and irreversible inhibitor of the enzyme CYP17 is effective in treating men with castration-resistant prostate cancer. The study showed that the CYP17 can reduce the...

  • Prostate cancer management shows major shifts in PSA era. Dosa, Laszlo // Urology Times;5/1/2005, Vol. 33 Issue 5, p9 

    This article discusses the trends in prostate cancer management discussed by experts at a session of the 2005 Multidisciplinary Prostate Cancer Symposium held in Orlando, Florida. The management of localized prostate cancer has undergone a significant, dramatic shift in recent years. Both pure...

  • New adjusted cut-off level for serum prostate specific antigen. Wiwanitkit, V. // Indian Journal of Cancer;Jan-Mar2011, Vol. 48 Issue 1, p110 

    The article discusses the new adjusted cut-off level for serum prostate specific antigen (PSA). It mentions the limitation on the application of the new derived adjusted PSA cut-off value and explores its specific trade-offs. It also notes that PSA derivatives and prostate specific antigen...

  • Debate Continues on Use of PSA Testing for Early Detection of Prostate Cancer. Friedrich, M. J. // JAMA: Journal of the American Medical Association;6/8/2011, Vol. 305 Issue 22, p2273 

    This article discusses the debate on the use of prostate-specific antigen (PSA) testing for the early detection and treatment of prostate cancer in the U.S. It attributes the failure of the adoption of PSA testing to criticism that it is an imperfect screening tool because it does not...

  • Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients. Sterzing, Florian; Kratochwil, Clemens; Fiedler, Hannah; Katayama, Sonja; Habl, Gregor; Kopka, Klaus; Afshar-Oromieh, Ali; Debus, Jürgen; Haberkorn, Uwe; Giesel, Frederik L. // European Journal of Nuclear Medicine & Molecular Imaging;Jan2016, Vol. 43 Issue 1, p34 

    Purpose: Radiotherapy is the main therapeutic approach besides surgery of localized prostate cancer. It relies on risk stratification and exact staging. This report analyses the potential of [Ga]Glu-urea-Lys(Ahx)-HBED-CC (Ga-PSMA-11), a new positron emission tomography (PET) tracer targeting...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics